Literature DB >> 7562006

Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas.

D J Stewart1, S Dahrouge, M Wee, S Aitken, H Hugenholtz.   

Abstract

The majority of meningiomas are cured by surgical resection. There is little information in the literature on the use of chemotherapy in meningiomas. We report 2 patients with inoperable recurrences of meningiomas that responded (1 patient) or stabilized (1 patient) when treated with the combination of intracarotid cisplatin plus intravenous doxorubicin.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7562006     DOI： 10.1007/BF01078489

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  14 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  Combined intraarterial and systemic chemotherapy for intracerebral tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; N Russell; M Richard; B Benoit
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

3.  Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; V DaSilva; M T Richard; B Benoit; G Belanger; N Russell
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

4.  Platinum concentrations in human autopsy tumor samples.

Authors:  D J Stewart; N Z Mikhael; R C Nair; S Kacew; V Montpetit; A Nanji; J A Maroun; K Howard
Journal:  Am J Clin Oncol       Date:  1988-04       Impact factor: 2.339

Review 5.  Pros and cons of intra-arterial chemotherapy.

Authors:  D J Stewart
Journal:  Oncology (Williston Park)       Date:  1989-10       Impact factor: 2.990

6.  A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors.

Authors:  D J Stewart; S Wallace; L Feun; M Leavens; S E Young; S Handel; G Mavligit; R S Benjamin
Journal:  Cancer Res       Date:  1982-05       Impact factor: 12.701

7.  Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).

Authors:  D J Stewart; R S Benjamin; S Zimmerman; R M Caprioli; S Wallace; V Chuang; D Calvo; M Samuels; J Bonura; T L Loo
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Radiation therapy in the treatment of partially resected meningiomas.

Authors:  N M Barbaro; P H Gutin; C B Wilson; G E Sheline; E B Boldrey; W M Wara
Journal:  Neurosurgery       Date:  1987-04       Impact factor: 4.654

9.  High dose doxorubicin plus cisplatin in the treatment of unresectable mesotheliomas: report of four cases.

Authors:  D J Stewart; S Z Gertler; A Tomiak; F Shamji; R Goel; W K Evans
Journal:  Lung Cancer       Date:  1994-09       Impact factor: 5.705

10.  Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary and metastatic brain tumors.

Authors:  D J Stewart; Z Grahovac; B Benoit; D Addison; M T Richard; J Dennery; H Hugenholtz; N Russell; E Peterson; J A Maroun
Journal:  Neurosurgery       Date:  1984-12       Impact factor: 4.654
View more
  3 in total

Review 1.  Chemotherapy for meningiomas.

Authors:  A P Kyritsis
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

Review 2.  Treatment of meningioma: an update.

Authors:  Anthony L D'Ambrosio; Jeffrey N Bruce
Journal:  Curr Neurol Neurosci Rep       Date:  2003-05       Impact factor: 5.081

3.  Transient cerebral hypoperfusion enhances intraarterial carmustine deposition into brain tissue.

Authors:  Shailendra Joshi; Mei Wang; Joshua J Etu; Raymond F Suckow; Thomas B Cooper; Steven J Feinmark; Jeffrey N Bruce; Robert L Fine
Journal:  J Neurooncol       Date:  2007-07-17       Impact factor: 4.506
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.